Last Update 10 Jul 26
Fair value Increased 2.33%ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion
AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision.
Analyst Commentary
Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition. Together these help explain why price targets have shifted and why views on execution risk still matter.
Bullish Takeaways
- Bullish analysts lifting AbbVie price targets into the mid to high US$200s tie their views to updated Q2 models and expectations that large cap biopharma peers could post broadly solid results, which they see as supportive for AbbVie’s earnings power and valuation.
- The planned US$10.9b Apogee deal is framed as a good fit with AbbVie’s existing immunology franchise, with several research notes highlighting atopic dermatitis and respiratory drugs as potential long term growth drivers that could justify higher long run assumptions in their models.
- Some bullish analysts point to AbbVie’s experience in dermatology and immunology sales as an execution advantage, arguing that this commercial footprint could help realize value from Apogee’s atopic dermatitis asset and sustain AbbVie’s competitive position against established therapies.
- Reports describing a bid for Apogee as sensible suggest investors may see the acquisition as supportive for AbbVie’s stock, particularly relative to peers that could face more pressure from increased competition in atopic dermatitis.
Bearish Takeaways
- Even among bullish analysts, there is acknowledgment that recent momentum across large cap biopharmas may be partly tied to investor rotation away from AI stocks rather than purely to fundamentals. This could limit how much multiple expansion AbbVie can sustain if sentiment shifts.
- One research note explicitly questions the sustainability of potential FY26 top line guidance raises across the group, signaling that AbbVie’s longer term growth trajectory is still being tested against patent cycles, pipeline execution and competitive threats.
- While the Apogee acquisition is seen as attractive for AbbVie, other analysts describe it as a net negative for competitors. This indirectly flags the risk that AbbVie will also face a more crowded field if additional large pharma companies respond with their own deals or pipeline pushes.
- Target cuts, such as a move down to about US$235 at one firm, underline that not all research is leaning one way, and that valuation sensitivity remains high around AbbVie’s pace of pipeline progress, integration of Apogee and future guidance updates.
What’s in the News for AbbVie
- AbbVie agreed to acquire Apogee Therapeutics in an all cash deal worth about US$10.9b, aiming to add Apogee’s atopic dermatitis and respiratory candidates, including lead drug zumilokibart, to AbbVie’s immunology and respiratory pipeline, with closing targeted for Q3 2026, according to the company and multiple news outlets.
- The European Commission approved Tepkinly, epcoritamab, in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma after at least one prior systemic therapy, following Phase 3 data showing improved progression free survival and response rates versus the standard R2 regimen, based on AbbVie and Genmab disclosures.
- Regulators in Europe and the U.S. advanced AbbVie’s immunology portfolio, with the EMA’s CHMP issuing positive opinions on Rinvoq for non segmental vitiligo and severe alopecia areata and authorities approving Skyrizi for pediatric plaque psoriasis and psoriatic arthritis, moves that expand AbbVie’s reach in dermatology and broader immune mediated conditions, as reported in company releases.
- AbbVie reported Q1 2026 revenue of US$15b, with growth driven by immunology drugs Skyrizi and Rinvoq that offset weaker Humira sales, and raised full year adjusted EPS guidance to a range of US$13.91 to US$14.11, according to the company’s quarterly update.
- A bipartisan U.S. House committee opened a national security investigation into AbbVie and other pharmaceutical companies focused on clinical trials in China linked to military affiliated sites and the Xinjiang region, requesting detailed documentation on due diligence, data protection and research practices, according to congressional letters cited in news reports.
Valuation Changes for AbbVie
- Fair Value: The updated analyst fair value estimate has risen slightly from about $253.55 to roughly $259.46 per share.
- Discount Rate: The applied discount rate has fallen slightly from about 7.48% to roughly 7.41%, which modestly increases the present value of AbbVie’s projected cash flows in these models.
- Revenue Growth: The modeled long term revenue growth assumption has edged up from about 7.94% to roughly 7.99%.
- Net Profit Margin: The projected net profit margin has stayed broadly stable, moving from about 28.76% to roughly 28.78%.
- Future P/E: The assumed future P/E multiple has risen slightly from about 24.48x to roughly 24.96x, indicating a modestly higher valuation multiple being applied to AbbVie’s earnings in these forecasts.
5 viewsusers have viewed this narrative update
Key Takeaways
- Strong performance in immunology and neuroscience, supported by new product launches and expanding indications, helps offset losses from older drugs facing competition.
- Strategic pipeline development, international growth, and operational efficiency position the company to sustain profitability and adapt to evolving industry trends.
- Over-reliance on a few key drugs and therapeutic areas heightens risk from competition, regulatory changes, and underperformance in R&D or acquisitions, threatening earnings stability.
Catalysts
About AbbVie
- A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
What are the underlying business or industry changes driving this perspective?
- Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high-need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top-line revenue growth and mitigate the impact of Humira's LOE.
- Advancements and strategic investments in neuroscience, including strong uptake of Vraylar, QULIPTA, Ubrelvy, and the emerging Parkinson's portfolio (e.g., VYALEV), align with growing demand for therapies addressing chronic neurological diseases in an aging population, supporting both revenue and long-term earnings stability.
- AbbVie's diversified and expanding late-stage and early-stage pipeline, coupled with consistent business development activity (e.g., Capstan in vivo CAR-T, Gubra amylin analog for obesity, next-gen siRNA platforms), positions the company to capitalize on the increasing adoption of biologics and specialty pharmaceuticals, which can reinforce premium pricing and protect net margins.
- International market expansion, evidenced by strong neuroscience launches and continued global share gains for Skyrizi and Rinvoq, provides opportunities for patient pool growth and revenue diversification as healthcare access broadens in emerging markets.
- Operational efficiency initiatives and focused cost management-alongside high adjusted gross and operating margins-are likely to sustain or improve net margins even as global pricing pressures mount, driving healthy underlying earnings growth.
AbbVie Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming AbbVie's revenue will grow by 8.0% annually over the next 3 years.
- Analysts assume that profit margins will increase from 5.7% today to 28.8% in 3 years time.
- Analysts expect earnings to reach $22.8 billion (and earnings per share of $13.04) by about July 2029, up from $3.6 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $28.2 billion in earnings, and the most bearish expecting $19.2 billion.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.0x on those 2029 earnings, down from 122.8x today. This future PE is greater than the current PE for the GB Biotechs industry at 17.5x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.41%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Loss of exclusivity and patent expirations for major products like HUMIRA-and eventual competitive pressures on follow-on blockbusters like Skyrizi and Rinvoq-could result in significant revenue declines as biosimilar and generic competition intensifies and erodes pricing power, directly impacting AbbVie's top-line growth and future earnings.
- Increasing global government focus on healthcare cost controls, drug price negotiations (such as the IRA in the US), and heightened regulatory scrutiny could lead to sustained pricing pressure, lower reimbursement rates, and rising compliance costs, putting downward pressure on net margins and earnings growth.
- Heavy reliance on a concentrated product portfolio (mainly immunology and neuroscience platforms) makes AbbVie vulnerable to pipeline setbacks, unforeseen safety concerns, or competitor breakthroughs in those therapeutic areas, which could destabilize long-term revenue and earnings diversification.
- Sustained weakness and volatility in the aesthetics business-driven by chronic macroeconomic headwinds, price-sensitive consumer trends, and shifting patient preferences-could limit recovery to historical growth rates and result in ongoing underperformance in that segment, negatively affecting revenue and margin contribution.
- Elevated R&D and acquisition spending needed to maintain future pipeline momentum introduces financial risk: if new therapies or recent strategic acquisitions (e.g., Capstan, Gubra) underperform or integration falls short, AbbVie could face pressured net margins and reduced return on investment, challenging its ability to drive long-term earnings growth.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $259.46 for AbbVie based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $328.0, and the most bearish reporting a price target of just $200.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $79.1 billion, earnings will come to $22.8 billion, and it would be trading on a PE ratio of 25.0x, assuming you use a discount rate of 7.4%.
- Given the current share price of $249.91, the analyst price target of $259.46 is 3.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on AbbVie?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives